PD33-05 TARGETED NEXT GENERATION SEQUENCING TO CHARACTERIZE MAGNETIC RESONANCE IMAGING VISIBLE AND INVISIBLE PROSTATE CANCER: BIOLOGICAL INSIGHTS AND THERAPEUTIC IMPLICATIONS

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology I1 Apr 2017PD33-05 TARGETED NEXT GENERATION SEQUENCING TO CHARACTERIZE MAGNETIC RESONANCE IMAGING VISIBLE AND INVISIBLE PROSTATE CANCER: BIOLOGICAL INSIGHTS AND THERAPEUTIC IMPLICATIONS Simpa Salami, Daniel Hovelson, Aaron Udager, Matthew Lee, Nicole Curci, Jeremy Kaplan, Arvin George, Matthew Davenport, Scott Tomlins, and Ganesh Palapattu Simpa SalamiSimpa Salami More articles by this author , Daniel HovelsonDaniel Hovelson More articles by this author , Aaron UdagerAaron Udager More articles by this author , Matthew LeeMatthew Lee More articles by this author , Nicole CurciNicole Curci More articles by this author , Jeremy KaplanJeremy Kaplan More articles by this author , Arvin GeorgeArvin George More articles by this author , Matthew DavenportMatthew Davenport More articles by this author , Scott TomlinsScott Tomlins More articles by this author , and Ganesh PalapattuGanesh Palapattu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.3319AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES While multiparametric magnetic resonance imaging (mpMRI) of the prostate has improved disease detection, up to 20% of patients with negative mpMRI harbor high grade prostate cancer (PCa). In this study, we sought to characterize and compare the molecular profiles of mpMRI visible and invisible PCa. METHODS Patients who underwent mpMRI prior to radical prostatectomy were identified for this IRB-approved study. mpMRI for each patient was reviewed by a radiologist with expertise in prostate mpMRI and histopathology reviewed by a genitourinary pathologist. Whole-mount histopathology was co-registered with axial mpMRI images. DNA and RNA were co-isolated from all tumor foci pre-identified on formalin-fixed paraffin-embedded specimens. High depth, targeted DNA and RNA next generation sequencing was performed to characterize the molecular profile of each tumor focus using the Oncomine Comprehensive Panel (DNA sequencing) and a custom targeted RNAseq panel assessing PCa relevant genes. RESULTS A total of 26 primary tumor foci from 10 patients were analyzed. The median number of PCa foci was 3. Of the 14 (54%) invisible lesions on mpMRI, 5 (36%) were Gleason 3+4=7 (Table 1). We detected high-confidence prioritized genetic mutations in 54% (14/26) of tumor foci, 43% (6/14) of which were in mpMRI-invisible lesions. Additionally, 64% (9/14) of lesions exhibiting prioritized mutations were Gleason 7. Notable point mutations were in APC, AR, ARID1B, ATM, ATRX, BRCA2, FAT1, MAP3K1, NF1, SPEN, SPOP, TP53, and a frameshift mutation was detected in SOX2. The expression profile of mpMRI visible and invisible lesions were similar (Figure 1). CONCLUSIONS We found no significant difference in the molecular profile of visible and invisible cancer foci on mpMRI. However, 36% of mpMRI invisible lesions exhibited biologically significant mutations. More work is needed to further characterize the molecular basis for mpMRI prostate cancer visibility. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e595 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Simpa Salami More articles by this author Daniel Hovelson More articles by this author Aaron Udager More articles by this author Matthew Lee More articles by this author Nicole Curci More articles by this author Jeremy Kaplan More articles by this author Arvin George More articles by this author Matthew Davenport More articles by this author Scott Tomlins More articles by this author Ganesh Palapattu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...